The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure.
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - Bristol-Myers Squibb; Halozyme; Ipsen
 
Paul Cockrum
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Andy Surinach
No Relationships to Disclose
 
Neil Lamarre
No Relationships to Disclose
 
Shu Wang
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Agios (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene; Center for Emerging & Neglected Diseases (CEND); CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); Incyte (I); Ipsen (I); Legend Biotech (I); Loxo; Merck; MINA THERAPEUTICS (I); Nerviano Medical Sciences (I); QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; Surface Oncology (I); TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Genentech (Inst); Roche (Inst); Silenseed (Inst)